Modified-Release Oral Minoxidil for Stable Serum Levels in Hair Loss

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for hair loss, such as topical minoxidil, often result in adverse effects and require frequent application, lacking a sustained release mechanism to maintain effective serum concentrations over time.

Innovation Solution

A modified release formulation of minoxidil or its pharmaceutically acceptable salt, designed for oral administration, which releases 50% to 98% of the daily dose within 12 hours, achieving a Tmax of 30 to 360 minutes and a Cmax of 0.25 ng/ml to 20 ng/ml, providing a controlled release mechanism.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If topical minoxidil is used to treat hair loss, then hair regrowth is achieved, but adverse effects occur and frequent application is required

Engineering Contradiction:

Improvehair regrowth effectivenessVSAvoidadverse effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the route of administration from topical to oral and modifies the release characteristics of minoxidil. The oral modified-release formulation achieves systematic delivery with controlled plasma concentration profiles, maintaining therapeutic levels while reducing the frequency of administration and minimizing local adverse effects associated with topical application

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The modified-release formulation provides continuous release of minoxidil over an extended period, maintaining sustained therapeutic plasma concentrations. This continuous action eliminates the need for frequent dosing while ensuring consistent hair regrowth effectiveness throughout the dosing interval

Inventive Principle:

Principle #20Continuity of useful action

2Reliability

If topical minoxidil is applied frequently to maintain effective serum concentrations, then therapeutic levels are achieved, but patient compliance decreases

Engineering Contradiction:

Improvetherapeutic serum concentration maintenanceVSAvoidfrequency of administration

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The modified-release formulation enables continuous release of minoxidil over 24 hours or longer, maintaining effective plasma concentrations throughout the dosing interval. This single daily dose regimen significantly improves patient compliance compared to multiple daily applications while ensuring reliable therapeutic effect

Inventive Principle:

Principle #20Continuity of useful action

Solution Approach 2:

The formulation is designed to release minoxidil in a controlled periodic manner, with initial release followed by sustained release over the dosing interval. This periodic action pattern maintains therapeutic levels without requiring frequent re-dosing

Inventive Principle:

Principle #19Periodic action

3Object-affected harmful factors

If a controlled release mechanism is implemented for minoxidil, then adverse effects are reduced, but formulation complexity increases

Engineering Contradiction:

Improveadverse effectsVSAvoidformulation complexity

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent employs modified-release technology with controlled dissolution and absorption characteristics. The formulation uses specific excipients and matrix structures to achieve controlled release kinetics, reducing peak plasma concentrations and associated adverse effects while maintaining therapeutic efficacy

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The minoxidil formulation is combined with various excipients including hydrophilic and hydrophobic polymers, buffers, and controlled-release matrices. This composite formulation approach enables precise control over drug release kinetics while managing the complexity through established pharmaceutical formulation techniques

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS20250360131A1Compositions and methods of use for modified release minoxidil

Publication Date: 2025.11.27 VERADERMICS INC

AI summary

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.